切换导航
  • 比较产品
我的购物车

EasySep™人CD138正选试剂盒 II

人CD138+细胞的免疫磁珠正选
率先评论此产品
添加并比较

产品号 #（选择产品）

产品号 #17877_C

人CD138+细胞的免疫磁珠正选

产品优势

  • 快捷 、操作简单
  • 无需分离柱     

产品组分包括

  • EasySep™人CD138正选试剂盒 II（产品号 #17877）
    • EasySep™人CD138正选试剂盒 II 抗体混合物，1 mL
    • EasySep™ Dextran RapidSpheres™ 50100 磁珠，1 mL
  • RoboSep™ 人CD138正选试剂盒 II（含过滤吸头，产品号 #17877RF）
    • EasySep™人CD138正选试剂盒 II 抗体混合物，1 mL
    • EasySep™ Dextran RapidSpheres™ 50100 磁珠，1 mL
    • RoboSep™ 缓冲液（产品号 #20104）
    • RoboSep™过滤吸头（产品号 #20125）
main product photo
New look, same high quality and support! You may notice that your instrument or reagent packaging looks slightly different from images displayed on the website, or from previous orders. We are updating our look but rest assured, the products themselves and how you should use them have not changed. Learn more
总览
实验数据
产品说明书及文档
应用领域
相关材料与文献
相关产品

总览

使用EasySep™人CD138正选试剂盒 II，通过免疫磁珠正选可从新鲜或冻存的人骨髓或外周血单个核细胞（MNC）中分离高纯度的CD138+（syndecan-1）细胞。EasySep™结合了单克隆抗体的特异性和无柱磁性系统的简便性，迄今已广泛应用于发表的研究中超过20年。    

在此EasySep™正选过程中，目的细胞被识别CD138的抗体四聚体复合物和磁珠结合标记，该抗体复合物中还含有人Fc受体阻断剂，可最大程度减少非特异性结合 。通过EasySep™磁极分离被标记的目的细胞，只需将非目的细胞倾倒或吸出，而目的细胞则被保留在管中。经磁珠分选后获得的CD138+细胞可直接用于流式细胞术、细胞培养或DNA/RNA提取等下游应用。CD138抗原在正常和恶性浆细胞表面表达（成熟B细胞不表达）。

该产品可替代EasySep™人CD138细胞正选试剂盒 (产品号 #18357     ) 以进行更快的细胞分选。

若需从全血和骨髓中分选CD138+细胞，推荐使用EasySep™人全血及骨髓CD138正选试剂盒（产品号 #17887）。

参加我们免费的CD138+细胞分选在线课程，学习如何处理骨髓样本并分选CD138+浆细胞以提高多发性骨髓瘤FISH检测的灵敏度。您还可以查阅关于CD138+浆细胞分选的常见问题解答（FAQs），了解如何提升FISH检测灵敏度。

了解更多关于免疫磁珠EasySep™技术的工作原理，或如何通过RoboSep™实现全自动化免疫磁珠细胞分选。探索更多优化您实验流程的产品，包括培养基、添加剂、抗体等。

磁体兼容性
• EasySep™ Magnet (Catalog #18000) • “The Big Easy” EasySep™ Magnet (Catalog #18001) • EasyEights™ EasySep™ Magnet (Catalog #18103) • RoboSep™-S (Catalog #21000)
 
亚型
细胞分选试剂盒
 
细胞类型
B 细胞，血浆
 
种属
人
 
样本来源
Bone Marrow，PBMC
 
筛选方法
Positive
 
应用
细胞分选
 
品牌
EasySep，RoboSep
 
研究领域
癌症，免疫
 

查看更多 显示更少

Data Figures

Typical EasySep™ Human CD138 Positive Selection Profile

Figure 1. Typical EasySep™ Human CD138 Positive Selection Profile

Starting with thawed PBMCs spiked with a multiple myeloma cell line, U266, the CD138+ cell content of the isolated fraction typically ranges from 93.0 - 98.2%. In the above example, the purities of the start and final isolated fractions are 9.16% and 94.34%, respectively.

Protocols and Documentation

Find supporting information and directions for use in the Product Information Sheet or explore additional protocols below.

Document Type
Product Name
Catalog #
Lot #
Language
Document Type
Product Information Sheet
Product Name
RoboSep™ Human CD138 Positive Selection Kit II
Catalog #
17877RF
Lot #
All
Language
English
Document Type
Product Information Sheet
Product Name
EasySep™ Human CD138 Positive Selection Kit II
Catalog #
17877
Lot #
All
Language
English
Document Type
Safety Data Sheet 1
Product Name
RoboSep™ Human CD138 Positive Selection Kit II
Catalog #
17877RF
Lot #
All
Language
English
Document Type
Safety Data Sheet 2
Product Name
RoboSep™ Human CD138 Positive Selection Kit II
Catalog #
17877RF
Lot #
All
Language
English
Document Type
Safety Data Sheet 3
Product Name
RoboSep™ Human CD138 Positive Selection Kit II
Catalog #
17877RF
Lot #
All
Language
English
Document Type
Safety Data Sheet 1
Product Name
EasySep™ Human CD138 Positive Selection Kit II
Catalog #
17877
Lot #
All
Language
English
Document Type
Safety Data Sheet 2
Product Name
EasySep™ Human CD138 Positive Selection Kit II
Catalog #
17877
Lot #
All
Language
English

Applications

This product is designed for use in the following research area(s) as part of the highlighted workflow stage(s). Explore these workflows to learn more about the other products we offer to support each research area.

Research Area
Workflow Stages

Resources and Publications

Educational Materials (14)

Tools for Cancer Research
Brochure
Tools for Cancer Research
Human B Cell Isolation Product Selection
Brochure
Human B Cell Isolation Product Selection
EasySep™ Cell Separation Technology
Brochure
EasySep™ Cell Separation Technology
Enhance Sensitivity of Multiple Myeloma Testing with Purified CD138+ Plasma Cells
Technical Bulletin
Enhance Sensitivity of Multiple Myeloma Testing with Purified CD138+ Plasma Cells
Human Hematopoietic Stem and Progenitor Cell Phenotyping
Wallchart
Human Hematopoietic Stem and Progenitor Cell Phenotyping
Small Molecules, Big Impact in Cancer Research
Wallchart
Small Molecules, Big Impact in Cancer Research
Human Immune Cytokines
Wallchart
Human Immune Cytokines
Frequencies of Human Cell Types in Blood-Related Sources
Wallchart
Frequencies of Human Cell Types in Blood-Related Sources
Automate Cell Isolation for Up to 16 Samples with the RoboSep™-16 Cell Separation Instrument
2:42
Video
Automate Cell Isolation for Up to 16 Samples with the RoboSep™-16 Cell Separation Instrument
Automate Cell Isolation with the RoboSep™-S Cell Separation Instrument
1:41
Video
Automate Cell Isolation with the RoboSep™-S Cell Separation Instrument
How EasySep™ Magnetic Cell Separation Technology Works: Fast and Easy Cell Isolation
1:57
Video
How EasySep™ Magnetic Cell Separation Technology Works: Fast and Easy Cell Isolation
Collaborating to Accelerate COVID-19 Research
3:36
Video
Collaborating to Accelerate COVID-19 Research
Plasma Cell Enrichment Prior to FISH Testing
32:14
Webinar
Plasma Cell Enrichment Prior to FISH Testing
CD138⁺ Cell Isolation Course
On-Demand Training
CD138⁺ Cell Isolation Course

Publications (14)

Comprehensive Characterization of the Multiple Myeloma Immune Microenvironment Using Integrated scRNA-seq, CyTOF, and CITE-seq Analysis. L. Yao et al. Cancer research communications 2022 oct

Abstract

UNLABELLED As part of the Multiple Myeloma Research Foundation (MMRF) immune atlas pilot project, we compared immune cells of multiple myeloma bone marrow samples from 18 patients assessed by single-cell RNA sequencing (scRNA-seq), mass cytometry (CyTOF), and cellular indexing of transcriptomes and epitopes by sequencing (CITE-seq) to understand the concordance of measurements among single-cell techniques. Cell type abundances are relatively consistent across the three approaches, while variations are observed in T cells, macrophages, and monocytes. Concordance and correlation analysis of cell type marker gene expression across different modalities highlighted the importance of choosing cell type marker genes best suited to particular modalities. By integrating data from these three assays, we found International Staging System stage 3 patients exhibited decreased CD4+ T/CD8+ T cells ratio. Moreover, we observed upregulation of RAC2 and PSMB9, in natural killer cells of fast progressors compared with those of nonprogressors, as revealed by both scRNA-seq and CITE-seq RNA measurement. This detailed examination of the immune microenvironment in multiple myeloma using multiple single-cell technologies revealed markers associated with multiple myeloma rapid progression which will be further characterized by the full-scale immune atlas project. SIGNIFICANCE scRNA-seq, CyTOF, and CITE-seq are increasingly used for evaluating cellular heterogeneity. Understanding their concordances is of great interest. To date, this study is the most comprehensive examination of the measurement of the immune microenvironment in multiple myeloma using the three techniques. Moreover, we identified markers predicted to be significantly associated with multiple myeloma rapid progression.
View publication
Targeting arginase-1 exerts antitumor effects in multiple myeloma and mitigates bortezomib-induced cardiotoxicity. K. Ramji et al. Scientific reports 2022 nov

Abstract

Multiple myeloma (MM) remains an incurable malignancy of plasma cells despite constantly evolving therapeutic approaches including various types of immunotherapy. Increased arginase activity has been associated with potent suppression of T-cell immune responses in different types of cancer. Here, we investigated the role of arginase 1 (ARG1) in V$\kappa$*MYC model of MM in mice. ARG1 expression in myeloid cells correlated with tumor progression and was accompanied by a systemic drop in EY-arginine levels. In MM-bearing mice antigen-induced proliferation of adoptively transferred T-cells was strongly suppressed and T-cell proliferation was restored by pharmacological arginase inhibition. Progression of V$\kappa$*MYC tumors was significantly delayed in mice with myeloid-specific ARG1 deletion. Arginase inhibition effectively inhibited tumor progression although it failed to augment anti-myeloma effects of bortezomib. However, arginase inhibitor completely prevented development of bortezomib-induced cardiotoxicity in mice. Altogether, these findings indicate that arginase inhibitors could be further tested as a complementary strategy in multiple myeloma to mitigate adverse cardiac events without compromising antitumor efficacy of proteasome inhibitors.
View publication
The surfaceome of multiple myeloma cells suggests potential immunotherapeutic strategies and protein markers of drug resistance. I. D. Ferguson et al. Nature communications 2022 jul

Abstract

The myeloma surface proteome (surfaceome) determines tumor interaction with the microenvironment and serves as an emerging arena for therapeutic development. Here, we use glycoprotein capture proteomics to define the myeloma surfaceome at baseline, in drug resistance, and in response to acute drug treatment. We provide a scoring system for surface antigens and identify CCR10 as a promising target in this disease expressed widely on malignant plasma cells. We engineer proof-of-principle chimeric antigen receptor (CAR) T-cells targeting CCR10 using its natural ligand CCL27. In myeloma models we identify proteins that could serve as markers of resistance to bortezomib and lenalidomide, including CD53, CD10, EVI2B, and CD33. We find that acute lenalidomide treatment increases activity of MUC1-targeting CAR-T cells through antigen upregulation. Finally, we develop a miniaturized surface proteomic protocol for profiling primary plasma cell samples with low inputs. These approaches and datasets may contribute to the biological, therapeutic, and diagnostic understanding of myeloma.
View publication
View All Publications

更多信息

更多信息
Species Human
Magnet Compatibility • EasySep™ Magnet (Catalog #18000) • “The Big Easy” EasySep™ Magnet (Catalog #18001) • EasyEights™ EasySep™ Magnet (Catalog #18103) • RoboSep™-S (Catalog #21000)
Sample Source Bone Marrow, PBMC
Selection Method Positive
标记抗体
  1. 抗人CD38抗体，克隆HIT2
    抗人CD38抗体，克隆HIT2

    小鼠单克隆IgG1抗体，抗人、黑猩猩、马CD38

  2. 山羊抗小鼠 IgG (H+L) 抗体，多克隆
    山羊抗小鼠 IgG (H+L) 抗体，多克隆

    抗小鼠IgG（H+L）山羊多克隆抗体

  3. 抗人CD45抗体，克隆HI30
    抗人CD45抗体，克隆HI30

    小鼠单克隆IgG1抗体，抗人、黑猩猩CD45

  4. 抗人CD138（Syndecan-1）抗体，克隆 MI15
    抗人CD138（Syndecan-1）抗体，克隆 MI15

    抗人、恒河猴、食蟹猴CD138（syndecan-1）的小鼠单克隆IgG1抗体

PRODUCTS ARE FOR RESEARCH USE ONLY AND NOT INTENDED FOR HUMAN OR ANIMAL DIAGNOSTIC OR THERAPEUTIC USES UNLESS OTHERWISE STATED. FOR ADDITIONAL INFORMATION ON QUALITY AT STEMCELL, REFER TO WWW.STEMCELL.COM/COMPLIANCE.
  • Scientists Helping Scientists™
  • ISO 13485 和 ISO 9001 质量管理体系认证
    ISO 14001 环境管理体系认证

Scientists Helping Scientists™

ISO 13485 和 ISO 9001 质量管理体系认证

ISO 14001 环境管理体系认证

版权 © 2025 STEMCELL Technologies 技术有限公司。保留所有权利。